Background: Circular RNAs (circRNAs) have important regulatory functions in cancer, but the role of circRNAs in the tumor microenvironment (TME) remains unclear. Moreover, we also explore the effects of si-circRNAs loaded in nanoparticles as therapeutic agent for anti-tumor in vivo. Methods: We conducted bioinformatics analysis, qRT-PCR, EdU assays, Transwell assays, co-culture system and multiple orthotopic xenograft models to investigate the expression and function of circRNAs. Additionally, PLGA-based nanoparticles loaded with si-circRNAs were used to evaluate the potential of nanotherapeutic strategy in anti-tumor response. Results: We identified oncogene SERPINE2 derived circRNA, named as cSERPINE2, which was notably elevated in breast cancer and was closely related to poor clinical outcome. Functionally, tumor exosomal cSERPINE2 was shuttled to tumor associated macrophages (TAMs) and enhanced the secretion of Interleukin-6 (IL-6), leading to increased proliferation and invasion of breast cancer cells. Furthermore, IL-6 in turn increased the EIF4A3 and CCL2 levels within tumor cells in a positive feedback mechanism, further enhancing tumor cSERPINE2 biogenesis and promoting the recruitment of TAMs. More importantly, we developed a PLGA-based nanoparticle loaded with si-cSERPINE2, which effectively attenuated breast cancer progression in vivo. Conclusions: Our study illustrates a novel mechanism that tumor exosomal cSERPINE2 mediates a positive feedback loop between tumor cells and TAMs to promote cancer progression, which may serve as a promising nanotherapeutic strategy for the treatment of breast cancer.
Introduction: Peritoneal metastasis (PM) remains a primary cause of poor prognosis in advanced gastric cancer (GC). While anoikis resistance enables detached tumor cells to survive and promotes invasion and metastasis, its specific mechanisms in GC related PM are not yet fully understood. Methods: Anoikis related differentially expressed genes were identified using GC samples from the TCGA and GEO databases. Molecular subtypes were characterized by non negative matrix factorization (NMF) clustering. Survival outcomes were assessed via Kaplan–Meier analysis, and functional profiles were evaluated through pathway enrichment scoring. A prognostic risk model was constructed by combining weighted gene co expression network analysis (WGCNA) with Lasso–Cox regression. For PM diagnosis, characteristic genes were screened using support vector machine (SVM) and random forest (RF) algorithms to build a diagnostic model. Experimental validation was performed to confirm the expression and functional role of SRPX2. Results: GC was stratified into two molecular subtypes. Subtype A showed marked enrichment of anoikis resistance related factors and was associated with significantly poorer prognosis. A six gene prognostic signature (HEYL, SRPX2, LBH, PLAT, ITGAV, HTRA1) was established and validated externally. A nine gene diagnostic panel (SLC30A9, ZFHX4, CYTB, NDFIP2, NMNAT2, SRPX2, TBC1D8B, CLEC3B, CHRDL2) was also constructed for PM. SRPX2 was identified as an independent prognostic marker and a PM associated biomarker, highly expressed in cancer associated fibroblasts (CAFs). Functional studies demonstrated that SRPX2 promotes GC progression and peritoneal metastasis by activating the FAK/AKT pathway and IL-6 paracrine signaling, thereby inducing anoikis resistance. Discussion: This study proposes an anoikis based molecular classification of GC and develops both prognostic and diagnostic models for PM. It further reveals that SRPX2 driven anoikis resistance, mediated through the FAK/AKT-IL-6 axis, facilitates peritoneal metastasis. These findings provide new directions for prognostic assessment and therapeutic strategies in gastric cancer.
Metastases are a primary cause of cancer-associated mortality; however, the mechanisms underlying aggressive progression have not been clearly elucidated. Genome-wide features of chromatin accessibility through ATAC-seq from HCC primary and metastatic tumors revealed that many distal regulatory elements spreading the genome become accessible during aggressive progression, the changes of which are associated with NFY-family. And NFYB is frequently upregulated in tumor with metastasis. Mechanistically, LINC01137 recruits SMYD3 to enhance H3K4me3 occupancy at IL-1β, CXCL2 and CCL20 promoters by inhibiting lysine ubiquitination to stabilize NFYB, which in turn upregulates IL-1β, CXCL2 and CCL20. HCC-derived cytokine transforms macrophages to the M2 phenotype to foster an inhibitory tumor microenvironment and anti-PDL1 tolerance. Importantly, LINC01137 transcription is activated by the NFYB/KAT2B complex in a feed-forward loop. Notably, treatment with an IL-1β inhibitor enhances the blockade efficacy of PD-L1 in NFYB-overexpressing HCC. Our findings imply an immunosuppressive role of NFYB–LINC01137 signaling during aggressive HCC progression and support the concept of microenvironment engineering in immunotherapy.
Background: Exercise therapy is a core intervention for knee osteoarthritis (KOA). For KOA patients, active and passive stretching exercises can relieve joint pain and restore joint function. Heel kicking exercise (HKE) is a dynamic stretching method designed by the authors to rapidly reduce knee pain and restore joint function in patients with KOA. This randomized controlled trial was conducted to determine the efficacy of HKE for pain and joint function in patients with KOA. Method: A total of 68 patients with KOA were included in this study. Eight patients were excluded, resulting in random allocation into a control group (N = 29, 1 lost to follow-up) and an observation group (N = 30). Both groups received traditional Chinese medicine hot compress therapy, oral administration of celecoxib capsules, and quadriceps contraction exercises. The control group additionally performed static stretching exercises targeting the quadriceps, hamstrings, and gastrocnemius muscles; conversely, the observation group performed in HKE. Changes in Western Ontario and McMaster Universities Osteoarthritis Index pain and stiffness indices, knee joint range of motion, Five-Times-Sit-to-Stand Test, Timed Up and Go Test, and Six-Minute Walk Test were assessed before treatment initiation and after 2 weeks. Results: Before treatment, there were no significant differences in the Western Ontario and McMaster Universities Osteoarthritis Index pain and stiffness score, joint range of motion, Five-Times-Sit-to-Stand Test, Timed Up and Go Test, and Six-Minute Walk Test levels between the 2 groups (P > .05). After treatment, the observation group outperformed the control group across all indicators (P < .05, P < .01). Patients’ satisfaction within 2 groups were investigated, which showed that patients’ satisfaction within the observation group were better than those in the control group (P < .01). Conclusions: HKE is an effective and safe exercise therapy that significantly alleviates knee pain in patients with KOA while restoring joint function.